All In Biotech

Drug Trial Radar · NCT01657162

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-003

Last checked: Nov 20, 2026Latest source record: Dec 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,139

Actual

Start

Nov 20, 2012

Primary completion

Oct 3, 2016

Study completion Oct 3, 2016

Sponsor

Lead sponsor
Radius Health, Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • AlendronateDrug

    Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With ≥1 New Vertebral Fracture Since Study BA058-05-003 BaselineTime frame: Study BA058-05-003 Baseline (Day 1) up to Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)

Locations

25 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Lakewood, Colorado

  • Site not named

    Hialeah, Florida

  • Site not named

    Bethesda, Maryland

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Brasília, Brazil

  • Site not named

    Curitiba, Brazil

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    Vitória, Brazil

  • Site not named

    Brno, Czechia

  • Site not named

    Brno-Vinohrady, Czechia

  • Site not named

    Pardubice, Czechia

  • Site not named

    Aalborg, Denmark

  • Site not named

    Ballerup Municipality, Denmark

  • Site not named

    Vejle, Denmark

  • Site not named

    Tallinn, Estonia

  • Site not named

    Tartu, Estonia

  • Site not named

    Hong Kong, Hong Kong

  • Site not named

    Vilnius, Lithuania

  • Site not named

    Bialystok, Poland

  • Site not named

    Kielce, Poland

  • Site not named

    Lodz, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Zgierz, Poland

  • Site not named

    Bucharest, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.